Unlocking Japan: Navigating Clinical Trials and Market Potential for Global Biopharma

As part of the “Developing Your New Medicine in Japan Faster” Virtual Event, CMIC Group sponsored a panel discussion on Japan’s evolving clinical trial landscape and its potential for global pharma and biotech companies.
As the world’s third-largest pharmaceutical market, Japan offers a clinical development environment comparable to the US and Europe. Recent data shows Japan’s PMDA New Active Substance median approval time is faster than the US FDA, with clinical trial start-up times of around 5 months, similar to Australia, Korea, and Taiwan.

Experts from leading clinical sites in Japan, global sponsors, and CMIC Group shared insights and real-life examples of:

• Patient recruitment strategies that leverage Japan’s unique healthcare infrastructure.
• Efficient site selection and management processes tailored for global sponsors.
• Seamless clinical trial execution with proven expertise in navigating challenges.
• Navigating Japan’s regulatory framework, including PMDA consultation processes.

Don’t miss this opportunity to learn how your company can successfully tap into the Japanese market and accelerate drug development – Download the free resource today.

This webinar is brought to you by CMIC Group.  For more information on CMIC Group, Japan’s top CRO, visit their website.

Follow CMIC on LinkedIn for the latest news and updates.